Cambridge Healthtech Institute’s 7th Annual
Cell Therapy Manufacturing
Scaling and Industrializing Cell-Based Therapies
August 26-27, 2020
CHI’s Cell Therapy Manufacturing meeting examines the practical challenges in manufacturing autologous and allogenic cell therapies at scale, with dedicated sessions on cell processing, scalability, next-generation production technologies, automation, closed systems, supply chain, and facility design. The meeting will feature extensive sessions on autologous and allogeneic production platforms, including CAR-Ts, NK cells, TCRs, TILs, and IPSCs at scale.
Cover will include, but is not limited to:
- Cell therapy manufacturng at commercial scale - what are the challenges?
- Manufacturing gene-edited CAR Ts, NK cells, TCRs
- Autologous manufacturing strategies
- Allogeneic manufacturing strategies
- Strategies for optimizing process development and reducing COGS - new technologies, automation, PAT
- Next-generation manufacturing technologies - end-to-end manufacturing
- Cell processing - bead and non-bead technologies, changing mid-process
- Implementing automated, closed, and integrated systems - moving from small- to large-scale
- Unique challenges in CAR T production - lentivirus supply, end-to-end manufacturing
- Centralized and decentralized manufacturing networks
- Operations and logistics
- Internal versus external manufacturing
- CMO management throughout development lifecycle - are there enough?
- Harvesting cells to and from manufacturing site
- Managing manufacturing execution systems and chain of custody
- Facility design and flexibility
- Supply chain security
* The program is subject to change without notice, due to unforeseen reason.